Chromosome locus 11q13 is commonly ampli®ed in human cancers including squamous carcinomas of the head and neck, lung and oesophagus, and carcinoma of the bladder and breast (Lammie and Peters, 1991; Peters et al., 1995) . This amplicon is large, spanning 2.5 ± 5 Mb, and harbours several genes with known oncogenic potential as well as a number of unde®ned genes. In breast cancer, 11q13 is ampli®ed in about 13% of primary tumours (Fantl et al., 1993) , and the majority of published studies have employed INT-2/ FGF-3 and HST-1/FGF-4 as DNA markers, since these were the ®rst putative oncogenes to be de®ned within the locus. Both INT-2/FGF-3 and HST-1/FGF-4 encode members of the ®broblast growth factor family (Delli Bovi et al., 1987; Dickson et al., 1989) , but these proto-oncogenes are infrequently expressed in tumours carrying 11q13 ampli®cation (Tsuda et al., 1989a; Fantl et al., 1990; Schuuring et al., 1992a) . More recently, CCND1 and EMS1 have been identi®ed as candidate oncogenes at this locus, since unlike INT-2 and HST-1, they are normally overexpressed in tumours ampli®ed at 11q13 (Schuuring et al., 1992a; Patel et al., 1996) . CCND1 is located within 125 ± 160 kb of both INT-2 and HST-1, but EMS1 is at least 800 kb telomeric to CCND1, and 640 kb telomeric to INT-2. Several studies have provided evidence that these genes and BCL1, the breakpoint locus for frequent t(11 : 14)(q13 : q32) translocations in B-cell neoplasms (Tsujimoto et al., 1984) , located 110 kb centrometric of CCND1, are coampli®ed (Schuuring et al., 1992a,b; Gaey et al., 1993; Schuuring, 1995) . However, it has been suggested by others that there may be as many as 4 dierent core amplicons at 11q13, de®ned by markers D11S97 and D11S146, CCND1, EMS1, and D11S833E, respectively (Karlseder et al., 1994) . Thus ampli®cation of particular loci within the amplicon may confer speci®c disease phenotypes and previous analyses of the eects of 11q13 ampli®cation may have pooled several distinct molecular pathologies.
Studies of EMS1 ampli®cation in squamous cell carcinoma of the head and neck reported an association with a more aggressive histology, including high cytologic grade and a diusely in®ltrative growth pattern . This led to the proposition that EMS1 ampli®cation might predict for early relapse and reduced overall survival (Meredith et al., 1995) . By contrast, in bladder cancer no association between EMS1 ampli®cation and other clinicopathological parameters was observed, but there was a trend for higher levels of EMS1 expression in super®cial bladder tumours than in invasive cancer (Bringuier et al., 1996) . Thus the consequences of EMS1 ampli®cation may dier with tumour type. In breast cancer, the only two studies that included EMS1 as a DNA marker for 11q13 ampli®cation noted general coampli®cation of EMS1 with the other 11q13 markers, and no independent analysis on the association of EMS1 ampli®cation and disease phenotype or outcome was reported (Schuuring et al., 1992b; Gaey et al., 1993) . However, the small sample size of 50 and 153 patients in these two studies limited the ability to detect any dierences between EMS1 and the other 11q13 markers which might have been apparent in a large population.
Some insight into potential phenotypes which might be conferred by EMS1 ampli®cation and overexpression can be inferred from the properties of the gene product. The EMS1 gene encodes the human homologue of cortactin, an 80/85 kDa protein ®rst identi®ed in chicken embryo ®broblasts (Wu et al., 1991) . Cortactin becomes heavily phosphorylated on tyrosine after cellular transformation by the v-src tyrosine kinase and this coincides with a change in localisation from the cytoplasm to abnormal focal adhesions termed podosomes. In studies of squamous carcinoma cell lines overexpressing EMS1, the EMS1 protein accumulates in podosome-like structures at the cellsubstratum junctions . Cortactin becomes tyrosine phosphorylated after treatment with epidermal growth factor (EGF), platelet derived growth factor (PDGF) or ®broblast growth factor (FGF), eects likely to be mediated by endogenous c-src (Maa et al., 1992; Zhan et al., 1993 Zhan et al., , 1994 . Interestingly, increased c-src activity commonly occurs in human breast cancers (Jacobs and Rubsamen, 1983; Rosen et al., 1986) . Thus increased EMS1 activity, as a result of gene ampli®cation and/or tyrosine phosphorylation may perturb cytoskeletal structures, perhaps resulting in impaired adhesion and metastasis.
Recently, we studied 11q13 ampli®cation using CCND1 and INT-2 as markers in a large cohort of about a thousand breast cancer patients with follow-up of more than 5 years. These data illustrated that CCND1 and INT-2 ampli®cation may predict early relapse in patients with node negative or estrogen receptor (ER) positive disease (Seshadri et al., 1996a) . This population has now been employed to determine if EMS1 ampli®cation can occur independently of CCND1 or INT-2 ampli®cation, and whether this confers a dierent phenotype as assessed by the relationship of EMS1 ampli®cation to several clinicopathological features of the population and patients' outcome.
Of 961 primary breast cancer samples analysed, 146 (15.2%) were ampli®ed for EMS1 as de®ned by a 5twofold increase in copy number and this is comparable with published studies of 11q13 amplification in primary breast cancer (Fantl et al., 1993) . Four hundred and sixty-two tumours (48%) were 521 mm in diameter, whereas 499 (52%) were 521 mm in diameter (Table 1) . Five hundred and forty-two tumours (56%) were stage I without axillary lymph node involvement. Of the 545 samples in which tumour grade was known, 81 were grade I, 242 were grade II and 222 were grade III. Estrogen and progesterone receptor (PgR) concentrations were available for all samples: 663 (69%) were ER positive and 632 (66%) were PgR positive. HER-2/ neu (c-erbB2) ampli®cation, p53 and Ki67 expression were available from previous studies on this series of patients: 109 (11%) had a 5threefold increase in HER-2/neu gene copy number (Seshadri et al., 1993) ; 160 (29%) were positive for p53 and 176 (32%) were positive for Ki67 (Seshadri et al., 1996b) .
Of the 747 tumours that were investigated employing all three gene markers i.e. CCND1, INT-2 and EMS1, in 40 (5.4%) EMS1 was co-ampli®ed with CCND1, in 59 (7.9%) EMS1 was coampli®ed with INT-2 and 50 (6.7%) showed EMS1 ampli®cation alone. EMS1 was ampli®ed in a total of 113 (15%). One hundred and seventy-nine samples (18.6%) were ampli®ed for at least one of the three markers. To determine to what degree the genes were ampli®ed concordantly, the relative ampli®cation at each locus was compared. Analysis of the association between CCND1 and INT-2 relative copy number among the 129 tumours which displayed ampli®cation of either of these two genes revealed a statistically signi®cant (P=0.0001) association ( Figure 1a ). It is not surprising that CCND1 and INT-2 are predominantly coampli®ed given their (Seshadri et al., 1993 (Seshadri et al., , 1996a . Comparisons of gene ampli®cation and other pathological parameters were carried out using the chi-square analysis of Fisher's exact test EMS1 amplification and phenotypes in breast cancer R Hui et al relatively close proximity at chromosome 11q13 (Tsuda et al., 1989b; Fantl et al., 1990; Theillet et al., 1990; Lammie and Peters, 1991; Schuuring et al., 1992a,b; Gaey et al., 1993; Karlseder et al., 1994; Seshadri et al., 1996a) . In view of suggestions for the existence of a number of amplicons within the 11q13 region that can be either ampli®ed independently or co-selected to amplify, the relationship between EMS1 and INT-2 was also examined. While some tumours showed similar degrees of ampli®cation for EMS1 and INT-2, the association was not signi®cant (P=0.1639) and 44% (50/113) of the population showed a high degree of EMS1 ampli®cation with little or no ampli®cation of INT-2 and vice versa (Figure 1b) . Covariance analysis showed that the slopes obtained from simple regression in Figure 1a and b were statistically dierent (P=0.0001). Similarly, there was no association between the degree of ampli®cation of EMS1 and CCND1. The lack of concordance in the degree of ampli®cation for EMS1 and INT-2 is consistent with previous data (Schuuring et al., 1992a; Karlseder et al., 1994) and additionally raises the possibility that there may be two phenotypes, one in which EMS1 is ampli®ed independently of CCND1 or INT-2 and another with coampli®cation of these loci. Since little work has been done to determine the prognostic signi®cance of EMS1 ampli®cation in breast cancer, we initially determined the relationship between EMS1 ampli®cation and several clinicopathological features and these data are summarized in Table 1 . There was a statistically signi®cant positive association between EMS1 ampli®cation and ER or PgR positivity (P=0.022 and 0.018, respectively). A strong positive correlation between 11q13 ampli®cation and ER positivity has previously been reported (Adnane et al., 1989; Fantl et al., 1990; Borg et al., 1991) , including two large studies with 41000 patients Seshadri et al., 1996a) . More recent studies have demonstrated a positive association between ER mRNA and cyclin D1 mRNA levels (Hui et al., 1996) and between ER positivity and cyclin D1 protein expression (Michalides et al., 1996) , but a relationship with EMS1 and ER gene expression has yet to be demonstrated. Two previous studies noted an association between 11q13 ampli®cation and younger patient age i.e. 450 years (Machotka et al., 1989; Tsuda et al., 1989a) , but the sample sizes in both studies were relatively small. Berns et al. (1994) , with a series of 661 patients and ®ve other smaller studies (Lidereau et al., 1988; Fantl et al., 1990; Borg et al., 1991; Schuuring et al., 1992b; Gaey et al., 1993) did not ®nd a relationship between 11q13 ampli®cation and patient age. Using INT-2 and CCND1 as ampli®cation markers in the same series of patients (n=1014), no association with age was detected (Seshadri et al., 1996a) . However, in this study EMS1 ampli®cation was observed more frequently in the older age group (550 years) (P=0.025) suggesting that the phenotypes conferred by ampli®cation of dierent DNA markers could be distinct. HER-2/neu amplification and overexpression is predominantly a feature of ER negative breast cancer (Borg et al., 1990; Seshadri et al., 1993) . Since EMS1 ampli®cation was strongly associated with ER positivity, it was perhaps not surprising that EMS1 and HER-2/neu gene ampli®cation were negatively correlated (P=0.01). No association was noted between EMS1 ampli®cation and tumour size, tumour grade, lymph node status, Ki67 or p53 expression.
A study recently completed in our laboratory indicated that EMS1 overexpression was largely due to EMS1 ampli®cation in primary breast cancer (Hui et al., 1997) , indicating that EMS1 ampli®cation is likely to identify overexpression of this gene. The date of last follow-up in the current study was taken as the censoring date for length of disease-free survival and overall survival for each patient. The median follow-up durations was 61 months, with a range of 0 to 109 months. Two hundred and twenty patients had died of breast cancer, and 323 patients had local or systemic relapses. Of the 542 patients with lymph-node negative Figure 1 Relationship between the relative copy numbers of (a) INT-2 and CCND1, (b) INT-2 and EMS1 among 179 primary breast cancers with ampli®cation of at least one of the three genes. Extraction and puri®cation of DNA, and slot-blot methodology were described previously (Seshadri et al., 1993) . Filters were hybridized with EMS1 cDNA probe (Schuuring et al., 1992a) as described previously (Buckley et al., 1993) , and the EMS1 signal on each autoradiograph was then measured by scanning densitometry, using a Bio-Rad model 620 video densitometer and Bio-Rad 1-D analyst software. The PgR (chromosome location 11q22) blots allowed correction for dierences in the amount of DNA loaded into each slot and distinction between ampli®cation and chromosome 11 polysomy. Each ®lter contained four slots with DNA from normal human peripheral-blood lymphocytes as controls. The ratio of EMS1 to PgR signal was used to compare tumour samples with the average of the four controls yielding`relative gene copy number'. Data on CCND1 and INT-2 ampli®cation were obtained from previously published studies on the same series of patients (Seshadri et al., 1996a) . The samples with 5twofold increase in gene copy number were excluded from the analysis. The relationships between EMS1, CCND1 and INT-2 copy numbers were assessed by simple regression and covariance analysis EMS1 amplification and phenotypes in breast cancer R Hui et al disease, 145 relapsed and 81 died. Using Cox univariate analysis, parameters including large tumour size (521 mm), axillary lymph node involvement (54 nodes), and absence of ER were all associated with increased risk of relapse and death from breast cancer (Table 2) . On the contrary, EMS1 ampli®cation (5two-or 5threefold increase in copy number) was not associated with increased risk of relapse or death from breast cancer ( Table 2) . Kaplan-Meier survival analysis and log-rank testing also indicated that EMS1 ampli®cation was not associated with increased relapse rate or death in the total population of 961 patients.
Data from our earlier study in the same series of patients suggested that CCND1 or INT-2 ampli®cation predicts for earlier relapse in patients with nodenegative or ER-positive breast cancers (Seshadri et al., 1996a) . Thus, the same subgroup analysis was performed to investigate whether there was a dierence in the disease phenotypes conferred by ampli®cation of EMS1 or CCND1/INT-2. A signi®cantly increased risk of relapse was observed in the node negative subgroup with EMS1 ampli®cation (both 5two-and 5threefold increase in copy number, P=0.028 and 0.008, respectively) ( Figure 2a ). In contrast, there was no increase in risk of relapse in patients with EMS1-ampli®ed, node-positive disease; rather there was a suggestion that patients in this subgroup have a decreased risk of relapse (P=0.066) (Figure 2b) . Unlike CCND1 or INT-2 ampli®cation, EMS1 ampli®cation was not associated with any increase in risk of relapse in the ER positive subgroup. However, a trend was evident in patients with ER negative tumours for an increased risk of relapse (Figure 3 ). Although this did not reach statistical signi®cance (at a 5threefold increase in copy number, P=0.073), perhaps as a consequence of the relatively small numbers in this subgroup, the curves clearly separated over the entire follow-up period. Despite a lack of evidence for increased risk of death in any of the subgroups with CCND1 or INT-2 ampli®cation (Seshadri et al., 1996a) , a trend was evident for increased risk of death in patients with EMS1 ampli®cation, in both the node negative and ER negative subgroups, (at a 5threefold increase in copy number, P=0.060 and 0.066 respectively) (Figure 4) .
Of the EMS1 ampli®ed tumours, a signi®cant fraction (44%) were ampli®ed for EMS1 alone. The data presented above suggested that within groups of the same ER status, ampli®cation of EMS1 might have biological consequences dierent from those resulting from ampli®cation of INT-2 or CCND1 (Seshadri et al., 1996a) . Therefore, to further investigate this possibility, the relapse-free survival of patients with EMS1 ampli®cation alone was compared with that of patients with INT-2 or CCND1 ampli®cation alone or with concurrent EMS1 ampli®cation. Despite the small number of samples in these subgroups, some interesting trends which may be of biological signi®cance were apparent. In ER positive tumours, ampli®cation of EMS1 alone appeared to be associated with improved relapse-free survival, whereas tumours harbouring CCND1/INT-2 ampli®cation, both in the presence and absence of concurrent EMS1 ampli®cation, tended to relapse earlier (Figure 5a ) in agreement with other published studies (Borg et al., 1991; Berns et al., 1995; Seshadri et al., 1996a) . Conversely, in ER negative tumours, EMS1 ampli®cation, both in the 1.6 ± 2.5 0.9 ± 1.6 1.6 ± 2.9 4.1 ± 7.9 1.2 ± 1. The number of samples included in the analysis and the cut o for each parameter are recorded in Table 1 . a EMS1 ampli®cation (n=961): 52 vs 5twofold increase in copy number. b EMS1 ampli®cation (n=961) : 53 vs 5threefold increase in copy number Figure 2 Kaplan ± Meier survival analysis of relapse-free survival of (a) axillary lymph node negative (N7) and (b) axillary lymph node positive (N+) subgroups. EMS1 ampli®cation: 5two-(*), 5two-(6), or 5three (*)-fold increase in copy number presence and absence of CCND1/INT-2 ampli®cation, conferred a worse prognosis than tumours ampli®ed for CCND1/INT-2 alone (Figure 5b) .
Data reporting relationships between 11q13 amplification and patients' outcome have been controversial. Three large studies (Borg et al., 1991; Berns et al., 1995; Seshadri et al., 1996a) employing INT-2 or CCND1 as markers, concluded that 11q13 amplification was associated with an increase in risk of breast cancer relapse in the node-negative and ER positive subgroups, but did not aect the overall survival in either subgroup or the total population. Similarly, the present study indicated that EMS1 ampli®cation was associated with earlier relapse in the node-negative subgroup. Given that only 56% of these tumours were also ampli®ed for CCND1 or INT-2, it is perhaps surprising that independent ampli®cation of genes with such divergent function appeared to confer similar phenotypes. A trivial explanation is that this re¯ects technical limitations in detecting ampli®cation by slot blot analysis on tumour DNA. However, the divergent eect of EMS1 and CCND/INT-2 ampli®cation in the ER subgroups argues against this interpretation. Thus the possibility cannot be excluded that the decreased relapse-free survival conferred in node negative patients and the trend for an improved relapse-free survival in node positive patients arise from an as yet unidenti®ed gene that is coampli®ed with either marker.
In marked contrast to studies with INT-2 or CCND1 that indicated an association between ampli®cation and early relapse in patients with ER positive tumours but not ER negative tumours, EMS1 ampli®cation was associated with an increase in risk of relapse and death in the ER negative but not the ER positive subgroup, although the total number of samples with amplification of EMS1 independent of concurrent INT-2 or CCND1 ampli®cation in the ER negative subgroup was small. However, the survival curves in Figure 5 suggested that patients with EMS1 ampli®cation alone appeared to fare better than patients with INT-2 or CCND1 ampli®cation in the ER positive subgroup Figure 3 Kaplan ± Meier survival analysis of relapse-free survival of ER negative subgroups. EMS1 ampli®cation: 5two-(*), 5two-(6), or 5three (*)-fold increase in copy number Figure 4 Kaplan ± Meier survival analysis of overall survival of (a) axillary lymph node negative and (b) ER negative subgroups. EMS1 ampli®cation: 5two-(*), 5two-(6), or 5three (*)-fold increase in copy number Figure 5 Kaplan ± Meier survival analysis of relapse-free survival of (a) ER positive and (b) ER negative subgroups. EMS1 ampli®cation alone (6), INT-2 or CCND1 ampli®cation with concurrent EMS1 ampli®cation (*), INT-2 or CCND1 amplification without concurrent EMS1 ampli®cation (*) irrespective of the presence of concurrent EMS1 ampli®cation. This implies that ampli®cation of EMS1 is of little functional signi®cance in ER positive breast cancer. In ER negative tumours, ampli®cation of EMS1 alone or in the presence of CCND1/INT-2 ampli®cation was accompanied by earlier relapse (Figure 5b ) which increased with gene dosage ( Figure  4b ) suggesting a functional relationship between EMS1 expression and poor prognosis. Some insight into a potential mechanism for this association comes from the suggestion that EMS1 may be involved in tumour cell mobility and invasion, due to its accumulation in podosome-like adhesion junctions in 11q13 ampli®ed carcinoma cells . Furthermore EMS1 function is modulated by tyrosine phosphorylation and in human breast cancer cell lines, tyrosine phosphorylation of EMS1 may be increased in cells with elevated c-src kinase activity, suggesting that EMS1 may mediate some of the eects of c-src in human breast cancer (Campbell et al., 1996) . There is accumulating evidence that increased cytosolic tyrosine kinase activity may predict for decreased relapse-free survival in breast cancer (Bolla et al., 1993; Romain et al., 1994) , and that c-src accounts for the majority of this activity (Ottenho-Kal et al., 1992) . Since EGF receptor and HER/neu positivity is negatively correlated with ER positivity Borg et al., 1990) , ER negative tumours are more likely to be EGF receptor positive or ampli®ed for the HER-2/neu gene with resultant activation of c-src (Muthuswamy et al., 1994; Osherov and Levitzki, 1994) . Thus ER negative tumours with EMS1 ampli®cation are likely to have both increased EMS1 protein and increased EMS1 tyrosine phosphorylation. This may lead to additive or synergistic eects on tumour cell invasion or metastasis and lead to an increased rate of relapse.
In conclusion, the present study raises the possibility that independent ampli®cation of EMS1 and CCND1 or INT-2 identify dierent phenotypes of breast cancer with dierent outcomes. This observation requires con®rmation and extension employing more accurate techniques for the detection of gene ampli®cation e.g. uorescinated in situ hybridization and by assessment of resultant changes in EMS1 gene expression. Concurrent studies of EMS1 overexpression in both ER positive and ER negative breast cancer cell lines may allow further insight into the functional consequences of EMS1 overexpression in breast cancer cells and shed more light on a functional role for EMS1 in the development and progression of some human cancers.
